ABOUT US
Fluigent owns or licences a portfolio of issued and pending patents worldwide (US, Canada, France, Europe, China and Japan), covering its core technologies in microfluidic flow control, Lab-on-a-chip devices and life science analysis (genetic testing, cell capture, etc).
Fluigent markets innovative matrices for capillary electrophoresis detection of unknow mutation. EMMATM technology allws unprecedented sensitivity, throughput and cost effectiveness. EMMATM is a high throughput screening method for both constitutional and somatic mutations.
All Fluigent range of microfluidic flow control systems are based on the patented FASTABTM technology combining software driven pressure and flow sensors in a true independent multichannel system.
Enabling full control of your microfluidic systems through pressure, flow and electrical monitoring, Fluigent technologies provide innovating solutions for all your microfluidic and lab-on-a-chip applications such as droplet-based drug testing, chromatography, cells and parasites separation, fabrication and testing of SU-8 flow sensor, dielectophoresis, highly viscous fluids and liquid air manipulations, gene expression analysis in microdroplet, etc...
Besides, our knowledge in microfluidics combined with our experience in industrial partnerships help companies to turn their industrial projects into accurate and reliable instruments. Based on your needs and ideas, our engineering team provides all the technical expertise necessary to build fully automated systems including software development (design, programming and maintenance), mechanics, electronics, etc.
Fluigent products are worldwide distributed. Academic and industrial research laboratories are already using our range of products for research on microfluidics, microfluidic liquid handling but also in biology, physics, chemistry, and clinical diagnostic.
Fluigent net sales and headcount have been doubling every year since 2006.